Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 557

1.

Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry.

Verheugt FWA, Gao H, Al Mahmeed W, Ambrosio G, Angchaisuksiri P, Atar D, Bassand JP, Camm AJ, Cools F, Eikelboom J, Kayani G, Lim TW, Misselwitz F, Pieper KS, van Eickels M, Kakkar AK; GARFIELD-AF Investigators .

Eur Heart J. 2017 Dec 20. doi: 10.1093/eurheartj/ehx730. [Epub ahead of print]

PMID:
29281086
2.

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

Fox KAA, Lucas JE, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Kayani G, Oto A, Mantovani LG, Misselwitz F, Piccini JP, Turpie AGG, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators.

BMJ Open. 2017 Dec 21;7(12):e017157. doi: 10.1136/bmjopen-2017-017157.

3.

Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial.

Korjian S, Braunwald E, Daaboul Y, Verheugt F, Bode C, Tendera M, Jain P, Plotnikov A, Burton P, Gibson CM.

Eur Heart J Acute Cardiovasc Care. 2017 Dec 1:2048872617745003. doi: 10.1177/2048872617745003. [Epub ahead of print]

PMID:
29249166
4.

Early clinical outcomes as a function of use of newer oral P2Y12 inhibitors versus clopidogrel in the EUROMAX trial.

Huber K, Ducrocq G, Hamm CW, van 't Hof A, Lapostolle F, Coste P, Gordini G, Steinmetz J, Verheugt FWA, Adgey J, Nibbe L, Kaniĉ V, Clemmensen P, Zeymer U, Bernstein D, Prats J, Deliargyris EN, Gabriel Steg P.

Open Heart. 2017 Nov 28;4(2):e000677. doi: 10.1136/openhrt-2017-000677. eCollection 2017.

5.

International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries.

Steinberg BA, Gao H, Shrader P, Pieper K, Thomas L, Camm AJ, Ezekowitz MD, Fonarow GC, Gersh BJ, Goldhaber S, Haas S, Hacke W, Kowey PR, Ansell J, Mahaffey KW, Naccarelli G, Reiffel JA, Turpie A, Verheugt F, Piccini JP, Kakkar A, Peterson ED, Fox KAA; GARFIELD-AF; ORBIT-AF Investigators.

Am Heart J. 2017 Dec;194:132-140. doi: 10.1016/j.ahj.2017.08.011. Epub 2017 Aug 24.

6.

High T2-weighted signal intensity for risk prediction of sudden cardiac death in hypertrophic cardiomyopathy.

Gommans DHF, Cramer GE, Bakker J, Dieker HJ, Michels M, Fouraux MA, Marcelis CLM, Verheugt FWA, Timmermans J, Brouwer MA, Kofflard MJM.

Int J Cardiovasc Imaging. 2017 Oct 23. doi: 10.1007/s10554-017-1252-6. [Epub ahead of print]

PMID:
29063221
7.

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.

Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN; ESC Scientific Document Group.

Eur J Cardiothorac Surg. 2018 Jan 1;53(1):34-78. doi: 10.1093/ejcts/ezx334. No abstract available.

PMID:
29045581
8.

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).

Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies.

Eur Heart J. 2017 Aug 26. doi: 10.1093/eurheartj/ehx419. [Epub ahead of print] No abstract available.

PMID:
28886622
9.

Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study.

Ferreira JP, Duarte K, Montalescot G, Pitt B, de Sa EL, Hamm CW, Flather M, Verheugt F, Shi H, Turgonyi E, Orri M, Rossignol P, Vincent J, Zannad F.

Clin Res Cardiol. 2018 Jan;107(1):49-59. doi: 10.1007/s00392-017-1157-3. Epub 2017 Aug 29.

PMID:
28852839
10.

Update on antithrombotic therapy after percutaneous coronary revascularisation.

Cuisset T, Verheugt FWA, Mauri L.

Lancet. 2017 Aug 19;390(10096):810-820. doi: 10.1016/S0140-6736(17)31936-0. Review.

PMID:
28831996
11.

Erratum to: Antiplatelet therapy with CABG: chaos in the Netherlands.

Verheugt FWA.

Neth Heart J. 2017 Sep;25(9):481. doi: 10.1007/s12471-017-1031-y. No abstract available.

12.

Antiplatelet therapy with CABG: chaos in the Netherlands.

Verheugt FWA.

Neth Heart J. 2017 Sep;25(9):479-480. doi: 10.1007/s12471-017-1022-z. No abstract available. Erratum in: Neth Heart J. 2017 Aug 9;:.

13.

Off-Label Use of Non-Vitamin K Antagonist Oral Anticoagulants.

van Vugt SPG, Brouwer MA, Verheugt FWA.

J Am Coll Cardiol. 2017 May 23;69(20):2577-2578. doi: 10.1016/j.jacc.2017.01.073. No abstract available.

PMID:
28521898
14.

Appropriateness of Oral Anticoagulants for the Long-Term Treatment of Atrial Fibrillation in Older People: Results of an Evidence-Based Review and International Consensus Validation Process (OAC-FORTA 2016).

Wehling M, Collins R, Gil VM, Hanon O, Hardt R, Hoffmeister M, Monteiro P, Quinn TJ, Ropers D, Sergi G, Verheugt FWA.

Drugs Aging. 2017 Jul;34(7):499-507. doi: 10.1007/s40266-017-0466-6. Review.

PMID:
28493216
15.

Letter by Damen et al Regarding Article, "A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More?"

Damen SAJ, Brouwer MA, Verheugt FWA.

Circulation. 2017 May 9;135(19):e1035-e1036. doi: 10.1161/CIRCULATIONAHA.116.026985. No abstract available.

PMID:
28483836
16.

Early Invasive Versus Selective Strategy for Non-ST-Segment Elevation Acute Coronary Syndrome: The ICTUS Trial.

Hoedemaker NPG, Damman P, Woudstra P, Hirsch A, Windhausen F, Tijssen JGP, de Winter RJ; ICTUS Investigators.

J Am Coll Cardiol. 2017 Apr 18;69(15):1883-1893. doi: 10.1016/j.jacc.2017.02.023.

17.

Bivalirudin in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: uncertainties almost clarified.

Huber K, Verheugt FW.

EuroIntervention. 2017 Mar 20;12(16):1930-1932. doi: 10.4244/EIJV12I16A315. No abstract available.

18.

Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial.

Hu PT, Lopes RD, Stevens SR, Wallentin L, Thomas L, Alexander JH, Hanna M, Lewis BS, Verheugt FW, Granger CB, Jones WS.

J Am Heart Assoc. 2017 Jan 17;6(1). pii: e004699. doi: 10.1161/JAHA.116.004699.

19.

Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.

Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GY, Cohen M, Husted S, Peterson ED, Fox KA.

N Engl J Med. 2016 Dec 22;375(25):2423-2434. doi: 10.1056/NEJMoa1611594. Epub 2016 Nov 14.

20.

Antithrombotic Therapy to Reduce Ischemic Events in Acute Coronary Syndromes Patients Undergoing Percutaneous Coronary Intervention.

Verheugt FW.

Interv Cardiol Clin. 2017 Jan;6(1):131-140. doi: 10.1016/j.iccl.2016.08.009. Review.

PMID:
27886817

Supplemental Content

Loading ...
Support Center